Dr. Wetzler on CDX-1401 in Combination with Decitabine in Patients with MDS

0 Views
administrator
administrator
07/04/23

Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses a phase I trial that studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next